Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Meta Cloud Ambitions Could Challenge AWS, Azure, and Google Cloud, Says Morgan Stanley 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
Super Micro Employees Detained in Taiwan AI Server Export Investigation 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Texas Man Charged After Fatal Tesla Full Self-Driving Crash in Katy 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
Kuaishou Stock Jumps as Kling AI Secures $2 Billion Funding Round 
Suncorp Cuts 2026 Premium Growth Forecast as Australia, New Zealand Markets Weaken 
Chinese Copper Foil Maker Londian Files U.S. IPO as EV Battery Demand Grows 
EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
Meta CEO Zuckerberg Says AI Agent Development Has Slowed Despite Massive AI Investment 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Hugel Inc. has forged a distribution partnership with Sihuan Pharmaceutical for its Letybo botulinum toxin product after becoming the first South Korean brand approved to enter the Chinese market.
China’s National Medical Products Administration recently approved Hugel's Letybo for local sales.
Sihuan Pharmaceutical, which has a network of over 10,000 hospitals and medical institutions, will expedite Hugel's entry into the Chinese botox market.
Hugel hopes to take a 30 percent share within three years of the product launch and is aspiring to become the top botox brand in the country.
The South Korean biopharmaceutical firm is also eyeing to enter the European market in 2021 and the US market in 2022.
The market is estimated to be worth 1.75 trillion won by 2025.
Hugel is now one of the four companies, including US’ Allergan, French company Ipsen’s Dysport, and Chinese company Lanzhou Institute of Biological Products’ Hengli, authorized to trade in the Chinese botox market.
Due to its continued economic growth and increasing attention for beauty and appearance, China is expected to have increased demand for BTX products.
